CHIX:COPNz (Ireland)
Â
Registered Shares
CHF
63.50
(0%)
Dec 27
Business Description
Cosmo Pharmaceuticals NV
ISIN : NL0011832936
Share Class Description:
CHIX:COPNz: Registered SharesCompare
Compare
Traded in other countries / regions
COPN.SwitzerlandCOPNz.UKC43.GermanyCOPN.AustriaCMOPF.USA IPO Date
2016-11-17Description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 91.69 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Interest Coverage | 22.09 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 5.98 | |||||
| Beneish M-Score | -2.89 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.1 | |||||
| 3-Year EBITDA Growth Rate | 34.5 | |||||
| 3-Year EPS without NRI Growth Rate | 19 | |||||
| 3-Year FCF Growth Rate | 43.1 | |||||
| 3-Year Book Growth Rate | -6.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 26.89 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 86.8 | |||||
| 9-Day RSI | 72.37 | |||||
| 14-Day RSI | 60.67 | |||||
| 6-1 Month Momentum % | -10.6 | |||||
| 12-1 Month Momentum % | 21.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.85 | |||||
| Quick Ratio | 4.48 | |||||
| Cash Ratio | 3.52 | |||||
| Days Inventory | 218.21 | |||||
| Days Sales Outstanding | 53.59 | |||||
| Days Payable | 181.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.19 | |||||
| Dividend Payout Ratio | 0.24 | |||||
| Forward Dividend Yield % | 3.19 | |||||
| 5-Year Yield-on-Cost % | 3.19 | |||||
| 3-Year Average Share Buyback Ratio | -3.6 | |||||
| Shareholder Yield % | 20.72 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 87.46 | |||||
| Operating Margin % | 47.18 | |||||
| Net Margin % | 37.8 | |||||
| FCF Margin % | 52.97 | |||||
| ROE % | 15.49 | |||||
| ROA % | 10.84 | |||||
| ROIC % | 13.16 | |||||
| ROC (Joel Greenblatt) % | 189.63 | |||||
| ROCE % | 16.35 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 14.74 | |||||
| Forward PE Ratio | 10.64 | |||||
| PE Ratio without NRI | 14.86 | |||||
| Shiller PE Ratio | 23.56 | |||||
| PS Ratio | 5.56 | |||||
| PB Ratio | 2.05 | |||||
| Price-to-Tangible-Book | 10.62 | |||||
| Price-to-Free-Cash-Flow | 10.51 | |||||
| Price-to-Operating-Cash-Flow | 8.78 | |||||
| EV-to-EBIT | 10.39 | |||||
| EV-to-Forward-EBIT | 8.66 | |||||
| EV-to-EBITDA | 8.95 | |||||
| EV-to-Forward-EBITDA | 7.59 | |||||
| EV-to-Revenue | 5.1 | |||||
| EV-to-Forward-Revenue | 3.94 | |||||
| EV-to-FCF | 9.14 | |||||
| Price-to-Projected-FCF | 4.01 | |||||
| Price-to-Median-PS-Value | 0.6 | |||||
| Price-to-Graham-Number | 2.7 | |||||
| Price-to-Net-Current-Asset-Value | 24.24 | |||||
| Earnings Yield (Greenblatt) % | 9.63 | |||||
| FCF Yield % | 9.19 | |||||
| Forward Rate of Return (Yacktman) % | 21.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cosmo Pharmaceuticals NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 177.398 | ||
| EPS (TTM) (CHF) | 4.152 | ||
| Beta | 1.41 | ||
| Volatility % | 38.5 | ||
| 14-Day RSI | 60.67 | ||
| 14-Day ATR (CHF) | 0.936741 | ||
| 20-Day SMA (CHF) | 60.81 | ||
| 12-1 Month Momentum % | 21.94 | ||
| 52-Week Range (CHF) | 50.6 - 80.4 | ||
| Shares Outstanding (Mil) | 16.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cosmo Pharmaceuticals NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cosmo Pharmaceuticals NV Stock Events
| Event | Date | Price(CHF) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cosmo Pharmaceuticals NV Frequently Asked Questions
What is Cosmo Pharmaceuticals NV(CHIX:COPNz)'s stock price today?
The current price of CHIX:COPNz is CHF63.50. The 52 week high of CHIX:COPNz is CHF80.40 and 52 week low is CHF50.60.
When is next earnings date of Cosmo Pharmaceuticals NV(CHIX:COPNz)?
The next earnings date of Cosmo Pharmaceuticals NV(CHIX:COPNz) is .
Does Cosmo Pharmaceuticals NV(CHIX:COPNz) pay dividends? If so, how much?
The Dividend Yield %  of Cosmo Pharmaceuticals NV(CHIX:COPNz) is 3.19% (As of Today), Highest Dividend Payout Ratio of Cosmo Pharmaceuticals NV(CHIX:COPNz) was 1.1. The lowest was 0.24. And the median was 0.91. The  Forward Dividend Yield % of Cosmo Pharmaceuticals NV(CHIX:COPNz) is 3.19%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers